Durability of Complete Responses in Patients from the ECHELON-3 …
Nov 5, 2024 · Results from the randomized, global, phase 3 ECHELON-3 study (NCT04404283) demonstrated a statistically significant and clinically meaningful improvement in OS, PFS, and objective response rate with brentuximab vedotin (BV) combined with lenalidomide (Len) and rituximab (R; BV+Len+R) vs placebo+Len+R in patients (pts) with R/R DLBCL after ≥2 ...
Pfizer Announces Positive Overall Survival in Phase 3 Trial of …
Mar 12, 2024 · ECHELON-3 is an ongoing, randomized, double-blind, multicenter Phase 3 study evaluating ADCETRIS plus lenalidomide and rituximab versus lenalidomide and rituximab plus placebo in adult patients with relapsed/refractory DLBCL, regardless of CD30 expression, who have received two or more prior lines of therapy and are ineligible for stem cell ...
Brentuximab Vedotin Combination for Relapsed Diffuse Large B …
Jan 7, 2025 · This phase 3 ECHELON-3 primary interim analysis compared the efficacy and safety of brentuximab vedotin versus placebo in combination with lenalidomide and rituximab (BV + Len + R v placebo + Len + R) for patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
ASCO 2024 – two more Echelon-3 surprises - ApexOnco
Jun 2, 2024 · Adcetris’s Echelon-3 trial in diffuse large B-cell lymphoma delivered two more surprises at its ASCO late-breaker yesterday. After Pfizer toplined an OS win its ASCO presentation revealed a positive PFS result too, as well as strong data in patients whose cancers didn’t express meaningful levels of CD30, the antigen Adcetris targets.
Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study. Background: Despite recent advances, there remains a …
Brentuximab Vedotin Improves Survival in Relapsed/Refractory …
Mar 12, 2024 · Findings from the phase 3 ECHELON-3 trial demonstrated that brentuximab vedotin plus lenalidomide and rituximab led to improvements in overall survival among patients with diffuse large B-cell lymphoma.
FDA approves brentuximab vedotin with lenalidomide and rituximab
Feb 12, 2025 · Approval was based on ECHELON-3 (NCT04404283), a randomized, double-blind, placebo-controlled trial enrolling 230 adult patients with relapsed or refractory LBCL who were ineligible to receive an...
Brentuximab Vedotin Combo Significantly Improves Survival in R/R …
Mar 12, 2024 · In the double-blind, multicenter ECHELON-3 trial (NCT04404283), 230 patients from North America, Europe, and the Asia-Pacific region were randomly assigned to receive brentuximab vedotin at 1.2 mg/kg intravenously every 3 weeks or matched placebo plus lenalidomide and rituximab.
ECHELON-3: Phase III, Placebo-Controlled Trial of Brentuximab …
Jun 6, 2024 · Interim analysis of results from the phase III ECHELON-3 study showed that the combination of brentuximab vedotin with lenalidomide and rituximab significantly improved overall survival, progression-free survival, and overall response rate compared with placebo plus lenalidomide and rituximab in patients with relapsed/refractory diffuse large B ...
U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for …
Feb 12, 2025 · ECHELON-3 is the first Phase 3 trial to demonstrate OS advantage over lenalidomide and rituximab plus placebo for patients with at least 2 prior lines of therapy with R/R diffuse large B-cell lymphoma ( DLBCL)